Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
94,401,153
-
Total 13F shares
-
54,057,835
-
Share change
-
-1,005,319
-
Total reported value
-
$974,084,774
-
Put/Call ratio
-
1918%
-
Price per share
-
$18.02
-
Number of holders
-
138
-
Value change
-
-$11,795,159
-
Number of buys
-
81
-
Number of sells
-
48
Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q2 2023
As of 30 Jun 2023,
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) was held by
138 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,057,835 shares.
The largest 10 holders included
Driehaus Capital Management LLC, BlackRock Inc., ORBIMED ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, STATE STREET CORP, PERCEPTIVE ADVISORS LLC, First Light Asset Management, LLC, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
138
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.